

Newsletter Number 12

17th March 2000

Information Circular for Pharmacists in Tasmania

Changes to the Tasmanian Poisons List Effective Date- 17th March 2000

Consistent with the recommendations of the National Drugs and Poisons Scheduling Committee (N.D.P.S.C.) the following changes come into effect in March 2000. Please note that this is a summary of the more notable changes and is not a full list. A copy of the Poisons List and the Poisons Act may be accessed via the internet site www.thelaw.tas.gov.au/. The Poisons Regulations are not available at this site but can be obtained by contacting 6233 2064 and an unofficial office copy can be provided by e-mail. Hard copies of all legislation are available from the Printing Authority of Tasmania (Tel: 6233 3289).

Schedule 2

New Entries

Amorolfine for topical use in preparations containing 0.25% or less of amorolfine (Note: This listing was adopted as part of the Trans Tasman Harmonisation process and a commercial product at 0.25% or less is not yet available in Australia. Please note that this does **not** include the nail lacquer which has a concentration of 5% and is therefore S3).

Isosorbide mononitrate-except in preparations for injection, which remain in Schedule 4.

Ketoprofen in preparations for dermal use.

Lodoxamide (Lomide Eye Drops) in preparations for ophthalmic use.

Amendments

Indomethacin in preparations for external use containing 1 per cent or less of indomethacin (previously only included spray preparations).

Isosorbide dinitrate- except in preparations for injection, which remain in Schedule 4.

Piroxicam in preparations for dermal use containing 1 per cent or less of piroxicam (previous concentration was 0.5% or less).

Sodium cromoglycate in preparations for nasal or ophthalmic use (previously only for nasal use).

Schedule 3

New Entries

Diclofenac in divided preparations for oral use containing 25mg or less of diclofenac per dosage unit in a pack containing 30 or less dosage units.

Inositol nicotinate -a compound which is converted to nicotinic acid in vivo.

Ketoprofen in divided preparations for oral use containing 25mg or less of ketoprofen per dosage unit in a pack containing 30 or less dosage units.

Metoclopramide when compounded with paracetamol in divided preparations, packed and labelled only for the treatment of nausea associated with migraine, in packs containing not more than 10 dosage units *.

Prochlorperazine tablets when manufactured, packed and labelled for buccal use, only for the treatment of nausea associated with migraine, in packs containing not more than 10 tablets. *

(* These preparations were moved to Schedule 3 as part of the Trans Tasman Harmonisation process. However, commercial products are not yet registered in Australia).

Amendments

Beclomethasone, Budesonide and Flunisolide aqueous nasal sprays- The Schedule 3 entries have been further qualified in that they are only included in this schedule when supplied in a pack containing 200 actuations or less and provided for adults and children 12 years and over.

Cimetidine, Famotidine, Nizatidine and Ranitidine- The qualification in these entries stating "as the only therapeutically active substance in preparations for oral use" has been removed. The new entries read ""for the relief of symptoms of gastro-oesophageal reflux, in packs containing not more than 14 days supply.

Minoxidil- The allowed concentration in Schedule 3 has now been raised. The new entry reads " Minoxidil in preparations for dermal use containing 5 per cent or less of minoxidil."

Schedule 4

New entries in Schedule 4 include:

Celecoxib (Celebrex capsules)- approved for the symptomatic treatment of osteoarthritis and rheumatoid arthritis.

Eptifibatide (Integrilin injection)- for the treatment of patients presenting with unstable angina.

Ibandronic acid (Bondronat Concentrate for intravenous infusion)- for the treatment of tumour induced hypercalcaemia, with or without metastases.

Leflunomide (Arava tablets)- for the treatment of active rheumatoid arthritis.

Tamsulosin (Omnic modified release capsules)- for the treatment of benign prostatic hyperplasia.

Telmisartan (Micardis/ Pritor tablets)- For the treatment of mild to moderate hypertension.

Additional Schedule 3 poisons permitted to be advertised

Amorolfine

Beclomethasone

S3R Substances (Regulation 34E)

The branch regularly receives calls regarding S3R substances. Listed below are the S3 items currently requiring recording:

1. Acepifylline
2. Aminophylline
3. Dihydrocodeine in undivided preparations
4. Insulin (proposed to move to S4 in December 2000)
5. Salbutamol
6. Terbutaline
7. Theophylline

List of Declared Restricted Substances (S4D)

Listed over the page is a consolidated list of S4D drugs. Please keep this available for reference.